Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.69 |
| ▸ | F10 | P00742 | 10/20 | 0.69 |
| ▸ | PLG | P00747 | 10/20 | 0.69 |
| ▸ | PLAU | P00749 | 10/20 | 0.69 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.69 |
| ▸ | PLAT | P00750 | 8/20 | 0.69 |
| ▸ | F7 | P08709 | 8/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.67 |
| ▸ | F3 | P13726 | 7/20 | 0.63 |
| ▸ | HPN | P05981 | 2/20 | 0.58 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292958 | 0.82 | F2 (1.00) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL29682938 | 0.81 | F2 (1.00) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL1325070 | 0.81 | F2 (1.00) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL7607415 | 0.80 | F2 (0.69) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL23752572 | 0.79 | F2 (0.78) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL7423002 | 0.79 | F2 (0.68) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL6690412 | 0.78 | F7 (1.00) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL7613273 | 0.76 | F7 (0.66) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL7484247 | 0.75 | F2 (0.71) | F2F10PLGPLAUPRSS1 | |
| SCHEMBL13208176 | 0.75 | F2 (1.00) | F2F10PLGPLAUPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020037912-A1 | FACTOR VIIA INHIBITORS | LEAHY ELLEN M (US) | 2002-03-28 | — | — | US | claimed |
| US-20020037912-A1 | FACTOR VIIA INHIBITORS | LEAHY ELLEN M (US) | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037912-A1 | FACTOR VIIA INHIBITORS | F7, F11, F5 | F2 12/4885F10 14/4885PLG 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.